RYTHM (RYM) Stock Price, News & Analysis

Company Overview

I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight.

Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.

Key Stats

• Today's Range: $12.53 to $14.21
• 50-Day Range: $13.76 to $25.71
• 52-Week Range: $12.53 to $50.38
• Volume: 17,939 shs
• Average Volume: 20,603 shs
• Market Capitalization: $29.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

RYTHM Stock Analysis - MarketRank™

RYTHM scored higher than 19% of companies evaluated by MarketBeat, and ranked 826th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

RYTHM has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

RYTHM has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of RYTHM is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RYTHM is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RYTHM has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of RYTHM has been sold short.

Short Interest Ratio / Days to Cover

RYTHM has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RYTHM has recently decreased by 11.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RYTHM does not currently pay a dividend.

Dividend Growth

RYTHM does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

RYTHM has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for RYTHM this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, RYTHM insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.48% of the stock of RYTHM is held by insiders.

Percentage Held by Institutions

5.98% of the stock of RYTHM is held by institutions.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RYM
• CIK: 1800637
• Web: rythminc.com
• Phone: (855) 420-0020
• Fax: N/A
• Employees: 141
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($5.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.26 million
• Net Margins: 9.84%
• Pretax Margin: -28.03%
• Return on Equity: 21.25%
• Return on Assets: 5.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.64
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: $17.28 million
• Price / Sales: 1.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $19.30 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 2,180,000
• Free Float: 2,104,000
• Market Cap: $29.99 million
• Optionable: N/A
• Beta: 9.94